Generated by AI
Cardiol Therapeutics Inc. Class A Common Shares represents an equity interest in Cardiol Therapeutics, a Canada-based clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for heart disease. The company’s current work centers on CardiolRx, a pharmaceutically manufactured oral cannabidiol formulation in clinical development for cardiovascular indications, including inflammatory heart conditions. Cardiol Therapeutics also advances related formulations and programs aimed at addressing the biological pathways involved in cardiac inflammation and fibrosis. Its business is concentrated in the biotechnology and pharmaceutical segments of the healthcare market, where it contributes to the development of specialized therapies for serious heart disorders. Based in Oakville, Ontario, Cardiol Therapeutics is positioned as a research-driven company with a narrow therapeutic focus on heart disease treatment.
Website2265 Upper Middle Road East
Oakville, ON, L6H 0G5
Canada
The latest articles about CRDL.
Detailed price information for Cardiol Therapeutics (CRDL-Q) from The Globe and Mail including charting and trades.
Detailed price information for Cardiol Therapeutics Inc (CRDL-T) from The Globe and Mail including charting and trades.
Summary of Oct 8's posts. Generated by AI.
Summary of Aug 26's posts. Generated by AI.
Summary of Aug 26's posts. Generated by AI.
Investors talking about CRDL also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.